PRAVEEN TIPIRNENI (CEO): What Surprised You Most in Series A Fundraising

Recent Posts

• Morphic Therapeutic Enters Into Integrin Research and Development Collaboration with Janssen
• Morphic Therapeutic to Present at 37th Annual J.P. Morgan Healthcare Conference
• AbbVie and Morphic Therapeutic Announce Collaboration Targeting Fibrotic Diseases
• Morphic Therapeutic Announces $80 Million Financing to Advance Next-Generation Oral Integrin Therapeutics through Clinical Proof of Concept
• High integrin affinity reached by hybrid domain deletion